6838 Stock Overview
A clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Formosa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$38.90 |
| 52 Week High | NT$66.90 |
| 52 Week Low | NT$36.90 |
| Beta | 1.1 |
| 11 Month Change | -11.09% |
| 3 Month Change | -0.26% |
| 1 Year Change | -23.12% |
| 33 Year Change | 14.41% |
| 5 Year Change | n/a |
| Change since IPO | -30.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6838 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -5.7% | 0.6% | -0.8% |
| 1Y | -23.1% | 9.2% | 29.0% |
Return vs Industry: 6838 underperformed the TW Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: 6838 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 6838 volatility | |
|---|---|
| 6838 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6838's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6838's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Erick Co | www.formosapharma.com |
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer.
Formosa Pharmaceuticals, Inc. Fundamentals Summary
| 6838 fundamental statistics | |
|---|---|
| Market cap | NT$5.87b |
| Earnings (TTM) | -NT$204.94m |
| Revenue (TTM) | NT$137.46m |
42.7x
P/S Ratio-28.7x
P/E RatioIs 6838 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6838 income statement (TTM) | |
|---|---|
| Revenue | NT$137.46m |
| Cost of Revenue | NT$21.13m |
| Gross Profit | NT$116.33m |
| Other Expenses | NT$321.27m |
| Earnings | -NT$204.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 84.63% |
| Net Profit Margin | -149.09% |
| Debt/Equity Ratio | 0% |
How did 6838 perform over the long term?
See historical performance and comparison